SLC6A6 and neoplasm: Recent studies have revealed that tumor cells promote progression by overexpressing the Tau transporter SLC6A6 to compete with CD8+ T cells for Tau, leading to T cell exhaustion and dysfunction; supplementation with Tau reverses this process [43].